10-Q: IMAC Holdings Faces Deepening Losses, Going Concern Doubt

IMAC Holdings reported a substantial increase in net loss and a worsening financial position, raising significant doubt about its ability to continue as a going concern.

Summary

• Net loss for the nine months ended September 30, 2025, significantly widened to $7.4 million, compared to $4.0 million for the same period in 2024.
• Revenues for the nine months ended September 30, 2025, decreased to $22,723 from $72,050 in the prior year period.
• The company's cash balance plummeted to $45,054 as of September 30, 2025, from $504,189 at December 31, 2024.
• Working capital deficit worsened to $(13.0) million as of September 30, 2025, from $(6.5) million at December 31, 2024.
• An impairment loss of $748,101 was recognized on laboratory equipment due to revenue shortfall and minimal cash flows.
• The company explicitly states substantial doubt about its ability to continue as a going concern for the next twelve months.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting resources and lack of segregation of duties.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, including deepening losses, rapidly depleting cash, a significant working capital deficit, and an explicit 'going concern' warning. Operational challenges are evident with minimal revenue from its new business segment and an impairment loss on recent acquisitions. Material weaknesses in internal controls further compound the negative outlook.

Negatives

• Net loss for the nine months ended September 30, 2025, increased by 85% to $7,398,666 from $3,995,271 in the prior year.
• Revenue for the nine months ended September 30, 2025, decreased by 68% to $22,723 from $72,050 in the prior year.
• Gross profit for the nine months ended September 30, 2025, was a loss of $(306,669), worsening from a loss of $(122,029) in the prior year.
• Operating loss for the nine months ended September 30, 2025, widened to $(6,762,613) from $(3,806,665) in the prior year.
• Cash balance decreased by 91% to $45,054 as of September 30, 2025, from $504,189 at December 31, 2024.
• Working capital deficit more than doubled to $(13.0) million as of September 30, 2025, from $(6.5) million at December 31, 2024.
• Total stockholders' deficit worsened to $(12,976,880) as of September 30, 2025, from $(5,638,525) at December 31, 2024.
• Net cash used in operating activities increased by 86% to $(3,762,188) for the nine months ended September 30, 2025, from $(2,025,227) in the prior year.
• An impairment loss of $748,101 was recognized on laboratory equipment due to a revenue shortfall and minimal cash flows.
• The company has significant current liabilities totaling $13.3 million, including $4.9 million to vendors, $0.5 million in dividends payable, $3.8 million in notes payable, and $4.0 million for discontinued operations liabilities.
• The company has identified material weaknesses in its internal control over financial reporting, including insufficient accounting resources and lack of segregation of duties.
• Ongoing legal proceedings related to alleged Medicare overpayments total approximately $4.3 million ($2.7M for Progressive Health, $0.5M for Advantage Therapy, $1.1M for IMAC St. Louis).

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to historical and expected operating losses and cash outflows.
• Inability to raise additional capital through debt or equity on favorable terms, or at all, could negatively impact financial condition and force delays, limits, reductions, or termination of development/acquisition activity, or even cessation of operations.
• The company is subject to ongoing legal proceedings and governmental audits related to alleged Medicare overpayments, which could result in significant financial liabilities (e.g., $2.7 million for Progressive Health, $0.5 million for Advantage Therapy, $1.1 million for IMAC St. Louis).
• Material weaknesses in internal control over financial reporting, including insufficient accounting resources and lack of segregation of duties, pose risks of material misstatements in financial statements and potential non-compliance with listing requirements.
• The company's future success depends on its ability to obtain additional financing for the projected costs associated with the growth of its recently acquired laboratory.
• The company's future success depends on its ability to attract competent, skilled laboratory and sales personnel at acceptable prices to manage overhead.
• Inflation has had a material impact on staffing and supply costs, and future inflation could adversely affect operating results and financial condition.

Future Outlook

The company anticipates needing to raise approximately $5.0 million in additional capital over the next 12 months to fund operations, including laboratory supplies, licenses, rent, utilities, insurance, and employee expenses. Over the next five years, estimated capital needs are $87 million, with an optimistic projection of $77 million from cash flow from operations and $10 million from outside resources. Management plans to raise additional capital through debt and equity to address the substantial doubt about its ability to continue as a going concern.

Management Comments

• Management plans to raise additional capital through the issuance of financial instruments including both debt and equity to mitigate the conditions and events that raise substantial doubt about continuing as a going concern.
• We anticipate expanding our accounting functions with dedicated staff and improving our internal accounting procedures and separation of duties when we can absorb the costs of such expansion and improvement with additional capital resources.
• Management will continue to observe and assess our internal accounting function and make necessary improvements whenever they may be required.

Industry Context

The company's pivot to precision medicine in cancer treatment, based on activated protein analysis, places it in a highly competitive and capital-intensive segment of the biotechnology and healthcare industry. While this field holds significant promise, the company's current financial distress, minimal revenue generation from its new laboratory, and substantial cash burn indicate severe challenges in establishing a viable market position and achieving commercial scale, especially compared to well-funded industry players.

Comparison to Industry Standards

• The company's revenue of $22,723 for nine months from its precision medicine segment is exceptionally low, indicating a nascent or struggling commercialization effort, far below typical revenue generation for established or even early-stage biotech companies with significant intellectual property.
• A net loss of $7.4 million on such minimal revenue suggests a highly inefficient cost structure or significant investment without corresponding returns, which is a red flag compared to industry benchmarks for sustainable growth.
• The rapid depletion of cash from $504,189 to $45,054 in nine months, coupled with a worsening working capital deficit of $(13.0) million, indicates severe liquidity issues that are far below the financial health standards of most publicly traded companies, even those in development stages.
• The recognition of a $748,101 impairment loss on laboratory equipment acquired in May 2024, just months after acquisition, due to 'revenue shortfall that resulted in minimal cash flows,' suggests a significant misjudgment in asset valuation or business strategy execution, which is atypical for successful industry acquisitions.
• The explicit 'going concern' disclosure and material weaknesses in internal controls are critical indicators of financial instability and operational deficiencies that would typically deter institutional investors and are not aligned with best practices in corporate governance for public companies.

Management Changes

Corporate Governance

Legal Proceedings

• Progressive Health & Rehabilitation, Ltd.: Company is appealing an alleged $2.7 million Medicare overpayment. A lawsuit was filed in federal court on May 14, 2025, and the case was remanded back to the Medicare Appeals Council on November 17, 2025.
• Advantage Therapy: Company is appealing an alleged $0.5 million Medicare overpayment and awaits a response from an Administrative Law Judge hearing conducted in February 2024.
• IMAC St. Louis: Company received notification of an estimated $1.1 million Medicare overpayment for the period February 26, 2020, through January 2, 2024.

Related Party Transactions

• A contract with a Board member to provide consulting services for $81,000 per quarter was terminated on September 15, 2025.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises, substantial losses, and the potential for the company to cease operations due to going concern issues. The stock price is highly likely to be negatively impacted.
• Creditors: Face increased risk due to the company's worsening financial condition, high current liabilities, and explicit going concern doubt.
• Employees: Potential job insecurity due to the company's financial distress and the need to manage overhead.
• Customers/Patients: Potential disruption of services if the company's financial situation deteriorates further or operations are curtailed.

Next Steps

• Management plans to raise additional capital through debt and equity financing.
• The company anticipates expanding its accounting functions with dedicated staff and improving internal accounting procedures and separation of duties when additional capital resources become available.
• The appeal for the Progressive Health overpayment case has been remanded back to the Medicare Appeals Council for a ruling on the merits.
• The company awaits the response from the Administrative Law Judge hearing for the Advantage Therapy overpayment case.

Key Dates

Recommendation

The company's financial health is in severe decline, marked by a substantial increase in net losses, rapidly diminishing cash reserves, and a worsening working capital deficit. The explicit 'going concern' warning, coupled with material weaknesses in internal controls and ongoing significant legal liabilities, indicates a high probability of further financial deterioration and potential operational failure. While the company is attempting to raise capital, the terms are likely to be highly dilutive, and the underlying business, despite a pivot to precision medicine, is generating minimal revenue and incurring significant impairment losses. These factors present an exceptionally high risk profile for investors, warranting a strong sell recommendation.

Keywords

IMAC Holdings, 10-Q, Quarterly Report, Financial Results, Net Loss, Going Concern, Cash Flow, Working Capital Deficit, SEC Filing, Biopharmaceutical, Oncology, Precision Medicine, Proteomics, Medicare Audit, Internal Controls, Capital Raise